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Abstract
Severe combined immunodeficiency (SCID) is classified as a primary immunodeficiency, which is characterized by impaired 
T-lymphocytes differentiation. IL2RG, IL7Ralpha, JAK3, ADA, RAG1/RAG2, and DCLE1C (Artemis) are the most defective 
genes in SCID. The most recent SCID therapies are based on gene therapy (GT) of hematopoietic stem cells (HSC), which 
are faced with many challenges. The new studies in the field of stem cells have made great progress in overcoming the 
challenges ahead. In 2006, Yamanaka et al. achieved "reprogramming" technology by introducing four transcription factors 
known as Yamanaka factors, which generate induced pluripotent stem cells (iPSC) from somatic cells. It is possible to apply 
iPSC-derived HSC for transplantation in patients with abnormality or loss of function in specific cells or damaged tissue, such 
as T-cells and NK-cells in the context of SCID. The iPSC-based HSC transplantation in SCID and other hereditary disorders 
needs gene correction before transplantation. Furthermore, iPSC technology has been introduced as a promising tool in 
cellular-molecular disease modeling and drug discovery. In this article, we review iPSC-based GT and modeling for SCID 
disease and novel approaches of iPSC application in SCID.
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Introduction
Severe combined immunodeficiency (SCID) is 
classified as a primary immunodeficiency (PID), which is 
characterized by impaired T-lymphocyte differentiation. 
SCID is a monogenic, heterogeneous, and life-threatening 
syndrome (1). Considering that both humoral and cellular 
adaptive immunity are involved, this immunodeficiency 
is called "combined" because in T-B- phenotypes of 
SCID, T-cell development, as well as B-cell development 
is affected. In T-B+ phenotypes, the absence of normal 
T-helpers leads to defective antibody production by 
normal B-cells. In some subtypes of SCID, the disease 
can also be accompanied by defective natural killer (NK) 
cells. These different phenotypes are due to mutations in 
several genes, which lead to appear in different stages of 
T-cell development (Fig.1). The worldwide prevalence 
of SCID is estimated to be in 50,000 to 100,000 of the 
young population and constitutes 7% of PID patients. 
Approximately 90% of genetic defects in different forms 
of SCID have been identified (2, 3). The latest therapies 
regarding SCID are based on gene therapies (Table 1), 
which so far are faced with many difficulties (4-18). 
The new studies in the field of stem cells  have made 
considerable progress in overcoming the challenges 
ahead. 
A review on induced pluripotent stem cell
In 2006, Takahashi et al. (19) achieved "Reprogramming" 
technology by introducing OCT4, KLF4, SOX2, and C-MYC 
reprogramming factors  (RFs), which are responsible for 
embryonic-like state, into human fibroblasts. These RFs, 
known as OKSM factors, generate induced pluripotent 
stem cells (iPSC) from a somatic cell and reverse its state 
back into embryonic status, which can later differentiate to 
various human cells. IPSC-derived pre-differentiated or 
differentiated cells can be used for transplantation in patients 
with abnormal or poorly functional specific cell lineage. 
Considering that harvested cells are autologous, there is no 
risk of immunological rejection (fully matched HLA-profile) 
and no concern regarding the low number of transplantable 
cells. Furthermore, preparing these pluripotent stem cells is a 
non-invasive method (20).
In addition to other aspects of iPSC-based therapies, there are 
various studies in the field of cancer and immunodeficiency that 
led to the creation of iPSC-derived cytotoxic T-lymphocytes 
(iCTL) and iNKT-Cells, which have major roles in the 
immune system. The medical applications of iPSC are not 
limited to cell therapy. Recently, iPSC technology has been 
introduced as a promising tool for in vitro cellular-molecular 
disease modeling, drug discovery, and ex-vivo regenerative 
medicine, including organogenesis and GT (21, 22).
